Bruker Corporation's (NASDAQ: BRKR) growth is backed by strong sales within its X-Ray and Nano Analytics businesses. Within the PCI division, expanding customer demand for pre-clinical MRI systems is highly encouraging. Meanwhile, the impact of macroeconomic pressure and currency fluctuation is likely to hurt the company's operational results.
In the past year, this Zacks Rank #3 (Hold) company's shares have gained 10.4% compared with the industry's 27.5% growth and the S&P 500 composite's 34.9% gain.
This renowned medical device company has a market capitalization of $11.77 billion. It has a 2025 earnings growth rate of 17.6%, which is much higher than the industry's 13.8% growth rate. BRKR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.1%.
Let's delve deeper.
Bruker's Key Upsides
Bright Prospects Within Nano Business Segment: The segment caters to a large set of customers, such as academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses that are involved in materials research and life science research analysis. The business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.
During the first half of 2024, the company's advanced X-Ray and Nano Analytics businesses delivered strong sales, backed by Nano's robust revenue growth. Nano's strong growth is driven by ...
